Leadership Team

m1-Mel Ehrlich.png

Mel Ehrlich, Ph.D., Chairman of the Board of Directors

Dr. Ehrlich from 2003 to 2014 was the CEO of Cytest Labs, Inc. Cytest Labs is a developer of Flow Cytometry instruments used in biologic cell and bacterial analysis, and from 2002 to 2003, he served as President and Chief Operating Officer of ARTES Medical, Inc., a San Diego-based, pre-FDA approval medical device company with a one-of-a-kind patented microsphere technology for permanent soft tissue bulking. ARTES was primarily targeting the large and underserved markets of deep facial wrinkles and scars.

From 1998 to 2002, Dr. Ehrlich was Vice President of SerOptix, Inc., Woburn, MA (formerly known as Laser Medical Corp.) for which he initiated its fluorescence spectroscopy program, which resulted in a technology for the rapid detection of infectious diseases in blood plasma. This "platform" technology had been developed using fluorescence spectroscopy and proprietary algorithms. The technology and instruments were designed to screen and protect the nation's blood supply from viruses such as HIV and Hepatitis C, among others.

Dr. Ehrlich has had patents granted in such diverse areas as a thermodynamically pumped laser, scanning microspectrophotometer, photochromics, batteries, “ArcPlugs” for gasoline-powered vehicles, and thin film technology. He has published and presented papers on these and other subjects.

Dr. Ehrlich received his B.S. from Long Island University and his Ph.D. from New York University. He is a member of the American Physical Society and New York Academy of Sciences.

Alan Alfieri, Vice President Scientific Affairs

Former Senior Associate and Clinical Associate Professor, Division of Radiation Oncology and Oncophysics within the Department of Radiation Oncology at the Montefiore Medical Center and the Albert Einstein College of Medicine, Clinical Associate Professor, NY Medical College, Westchester Medical Center, and Radiobiologist, Beth Israel Medical Center and Memorial Sloan Kettering Cancer Center, R&D on preclinical hyperthermia, radiation sensitization, and protection. Mr. Alfieri was instrumental in the early development and patent of a sustained release nitric oxide releasing nanoparticles as a novel delivery platform based on nitrate containing hydrogel/glass composites. This platform was further developed to increase the efficacy of chemotherapeutics to effectively treat Triple-Negative Breast Cancer Subtypes that were resistant to Doxorubicin and have always had a very low patient survival rate. Mr. Alfieri has collaborated and liaised extensively with regulatory agencies including the FDA, NIH, NCI, AID’s, DOD, AFFRI, for INDE, and collaborations with compliance institutions for new and enhanced biotechnology/biopharmaceutical product developments and approval. He has had active leadership in the design, development, and execution of both global and domestic clinical trials. Mr. Alfieri has authored and co-authored over two hundred scientific papers for national and international journals, books, and symposium proceedings and present findings/publications at national/int’l meetings.

m3_Dan Fisher.png

Dan Fisher, President

Mr. Fisher was the former CEO and co-founder of BioZone Laboratories, a GMP contract pharma and cosmetic manufacturer for more than 20 years with a strong reputation for product innovation. BioZone supplied top pharma companies medical grade skin care products which were nationally distributed in most major retailers.  The company was dedicated to developing customer-specific personalization and unique product solutions with advanced technologies. Mr. Fisher has 3 patents in drug delivery technology.

Elizabeth Kellogg, Vice President of Marketing, Member of the Board of Directors

Ms. Kellogg is an award-winning SVP Creative Director with an extensive global advertising and marketing background. She has worked for the past 25 years at several top-tier agencies such as JWT and BBDO. She has worked on a wide range of major brands from Mercedes-Benz to IKEA. Liz’s focus has been in the pharmaceutical arena and has been responsible for winning gold awards for clients such as Pfizer, Novartis, GlaxoSmithKline, and Ferring Pharmaceutical. Some of the brands that she launched include: Zyrtec, Zoloft, Zelnorm, Diovan, Lamisil, Lysteda and Avandia. She specializes in strategic planning and is responsible for all the 360 creative, from concept through to completion. Ms. Kellogg is currently Director and Professor at Pratt Institute, where she teaches Visual Communications to undergraduates.

Mr. Murray Froikin, Chief Financial Officer and Chief Operating Officer

Mr. Froikin, a principal in NMB Therapeutics, has strong business development expertise creating and launching new products, technology development, and licensing. He has a Harvard MBA in General Management and Finance.